GUEST COLUMNISTS

• Can Psychedelic‑Assisted Treatment Redefine Emotional Care In Oncology?

  Psychedelic-assisted treatment may offer faster, lasting relief for cancer patients facing adjustment disorder, depression, and anxiety.

• The U.S. Clinical Trial Recruiting Pipeline – September 2026

  This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from August to Septemeber.

• Unlocking AI Value For Clinical Research Associates

  Clinical research associates (CRAs) have largely been late to adopt AI. CRAs who adopt it can streamline repetitive work while also freeing capacity for high-judgment work.

• Your EDC Query Count Is Trying To Tell You Something

  A rising EDC query count may reveal more than dirty data. Learn how query patterns can expose upstream problems in trial workflows, training, and CRF design.

• Can A Universal Health Screening Help Stop Clinical Trial Dropouts?

  Could comprehensive health scans give trial participants meaningful value — and help sponsors reduce costly dropouts?

• Can Your Team Coordinate The CRO Model You've Chosen?

  Choosing the right CRO model matters less than a sponsor’s ability to coordinate it. Here’s how to match outsourcing strategy to internal capacity.

• To Pick The Right Medical LLM, First Assess Your Readiness

  Learn how to evaluate medical LLMs for clinical trials by weighing readiness, risk, validation, integration, hidden costs, and supplier controls.

• Your Company Needs Compliance Expertise — But When And From Whom?

  When should a biotech formalize compliance? Learn how risk, funding, clinical activity, and commercialization shape the right expertise and structure.